Welcome to our dedicated page for CareDx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CareDx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CareDx's regulatory disclosures and financial reporting.
On July 8, 2025, CareDx, Inc. (CDNA) director Michael Goldberg filed a Form 4 reporting receipt of 1,218 shares of common stock at a grant price of $0 under the company’s Outside Director Compensation Policy. The automatic equity award, issued in lieu of quarterly cash fees, raises his direct ownership to 154,216 shares. No open-market purchases, sales or derivative transactions were disclosed, indicating the filing is a routine governance matter rather than a signal of insider sentiment.
CareDx director Hannah Valantine has reported a significant insider transaction, selling 10,570 shares of common stock on June 18, 2025 at a weighted average price of $19.16 per share (ranging from $19.00 to $19.62). The total transaction value amounts to approximately $202,521.
The sale was executed under a Rule 10b5-1 trading plan established on December 12, 2024, which provides a pre-planned structure for insider trades. Following the transaction, Valantine retains direct ownership of 38,994 shares of CareDx common stock.
This transaction demonstrates a planned reduction in the director's holdings while maintaining a significant equity position in the company. The Rule 10b5-1 plan framework helps ensure compliance with insider trading regulations by establishing the trade parameters in advance.